Underactive Bladder Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharma

DelveInsight's "Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Underactive Bladder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Underactive Bladder Market Forecast
https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Underactive Bladder Market Report:
• The Underactive Bladder market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In October 2024, Iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura), announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS). This EFS aims to assess the safety and feasibility of an investigational implantable device intended to deliver electrical stimulation directly to the bladder wall, promoting contractions that aid in bladder emptying for individuals with underactive bladder (UAB).
• In 2023, within the EU4 (Germany, France, Italy, Spain) and the United Kingdom, Germany reported the highest diagnosed prevalent cases of underactive bladder (UAB), estimated at around 200,000 cases. This number is projected to rise by 2034.
• In 2023, there were approximately 14 million cases of moderate to severe lower urinary tract symptoms (LUTS) in Japan, with an estimated 180,000 diagnosed prevalent cases of underactive bladder (UAB). These diagnosed UAB cases are expected to decline in the forecast period from 2024 to 2034.
• TAC-302 and other emerging therapies have shown promising initial results in their clinical trials. Efforts to encourage research and development are crucial to overcome current limitations and promote market growth, especially given the limited options in the pipeline.
• Key Underactive Bladder Companies: Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others
• Key Underactive Bladder Therapies: TAC-302, MR-MC-01, ASP8302, TAC-302, and others
• The Underactive Bladder epidemiology based on gender analyzed that males predominantly has the higher number of diagnosed prevalent cases than females
• The Underactive Bladder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Underactive Bladder pipeline products will significantly revolutionize the Underactive Bladder market dynamics.

Underactive Bladder Overview
Underactive bladder (UAB), also known as detrusor underactivity (DU), is a condition characterized by reduced bladder contraction strength and/or duration, resulting in incomplete bladder emptying or a prolonged time to empty the bladder. This condition can lead to symptoms such as difficulty initiating urination, a weak urinary stream, the need to strain to urinate, incomplete bladder emptying, and urinary retention.

Get a Free sample for the Underactive Bladder Market Report:
https://www.delveinsight.com/report-store/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Underactive Bladder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Underactive Bladder Epidemiology Segmentation:
The Underactive Bladder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Prevalent cases of Lower urinary tract symptoms (LUTS) - moderate to severe in the 7MM
• Diagnosed Prevalent cases of Underactive Bladder (UAB) in the 7MM
• Gender-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM
• Classification-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM
• Etiology-specific Diagnosed Prevalent cases of Underactive Bladder in the 7MM

Download the report to understand which factors are driving Underactive Bladder epidemiology trends @ Underactive Bladder Epidemiology Forecast
https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Underactive Bladder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Underactive Bladder market or expected to get launched during the study period. The analysis covers Underactive Bladder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Underactive Bladder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Underactive Bladder Therapies and Key Companies
• TAC-302: TaihoPharmaceutical
• MR-MC-01: Mirae Cell Bio
• ASP8302: Astellas Pharma Europe B.V
• TAC-302: Taiho Pharmaceutical

Discover more about therapies set to grab major Underactive Bladder market share @ Underactive Bladder Treatment Market
https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Underactive Bladder Market Strengths
• The existing treatment paradigm consists mainly of off-label drugs. The untapped market for branded drugs presents lucrative avenues for market growth

Underactive Bladder Market Opportunities
• There is room for branded therapeutic modalities with good safety and efficacy data along with progressive clinical trials

Scope of the Underactive Bladder Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Underactive Bladder Companies: Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others
• Key Underactive Bladder Therapies: TAC-302, MR-MC-01, ASP8302, TAC-302, and others
• Underactive Bladder Therapeutic Assessment: Underactive Bladder current marketed and Underactive Bladder emerging therapies
• Underactive Bladder Market Dynamics: Underactive Bladder market drivers and Underactive Bladder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Underactive Bladder Unmet Needs, KOL's views, Analyst's views, Underactive Bladder Market Access and Reimbursement

To know more about Underactive Bladder companies working in the treatment market, visit @ Underactive Bladder Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Underactive Bladder Market Report Introduction
2. Executive Summary for Underactive Bladder
3. SWOT analysis of Underactive Bladder
4. Underactive Bladder Patient Share (%) Overview at a Glance
5. Underactive Bladder Market Overview at a Glance
6. Underactive Bladder Disease Background and Overview
7. Underactive Bladder Epidemiology and Patient Population
8. Country-Specific Patient Population of Underactive Bladder
9. Underactive Bladder Current Treatment and Medical Practices
10. Underactive Bladder Unmet Needs
11. Underactive Bladder Emerging Therapies
12. Underactive Bladder Market Outlook
13. Country-Wise Underactive Bladder Market Analysis (2020-2034)
14. Underactive Bladder Market Access and Reimbursement of Therapies
15. Underactive Bladder Market Drivers
16. Underactive Bladder Market Barriers
17. Underactive Bladder Appendix
18. Underactive Bladder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.